The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 329:1318-1327 October 28, 1993 Number 18
NextNext

Clinical Implications of the p53 Tumor-Suppressor Gene
Curtis C. Harris, and Monica Hollstein

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
The crucial differences between normal cells and cancer cells stem from discrete changes in specific genes controlling proliferation and tissue homeostasis. Over 100 such cancer-related genes have been discovered, several of which are implicated in the natural history of human cancer because they are consistently found to be mutated in tumors. The p53 tumor-suppressor gene is the most striking example because it is mutated in about half of almost all types of cancer arising from a wide spectrum of tissues. Other tumor-suppressor genes important in human cancers, such as adenomatous polyposis coli, Wilms' tumor type 1, and neurofibromatosis type 1, . . . [Full Text of this Article]

Molecular Mechanisms of p53 Function

Regulation of Transcription of Multiple Genes by the p53 Protein

Clues to the Mechanisms of Cancer Formation from p53 Mutation Patterns in Tumors

Molecular Archaeology: Analysis of Damage to the p53 Gene in Tumors as a Way of Investigating Causes of Cancer

p53 Mutation Profiles in Human Tumors

            Hepatocellular Carcinoma

            Squamous-Cell Carcinoma of the Skin

Approaches to Molecular Diagnosis, Prognosis, and Therapy

Correlation between the Accumulation of p53 Protein in Neoplastic Cells and the Presence of a Missense Mutation in the p53 Gene

Genetic Screening for Germline p53 Mutations

Immunocytochemical Staining with p53 Antibodies: Biomarker for Cancer

New Diagnostic Strategies Based on the Detection of p53 Antibodies in the Serum of Patients with Cancer

Prognostic Importance of p53 Mutations

Therapy Based on the Renewal of p53 Function


Source Information

From the National Cancer Institute, Laboratory of Human Carcinogenesis, Bethesda, Md. (C.C.H.), and the Unit of Mechanisms of Carcinogenesis, International Agency for Research on Cancer (World Health Organization), Lyons, France (M.H.).

Address reprint requests to Dr. Harris at the National Cancer Institute, Laboratory of Human Carcinogenesis, Bldg. 37, Rm. 2C01, Bethesda, MD 20892.

References


Related Letters:

Clinical Implications of the p53 Tumor-Suppressor Gene
Rutz H. P., Mirimanoff R. O., Bokemeyer C., Kuczyk M. A., Sehrt J., Muller M., Volkmann M., Zentgraf H., Galle P. R.
Extract | Full Text  
N Engl J Med 1994; 330:864-865, Mar 24, 1994. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.